A Whistle-Stop Tour of 2017 – From An EU Regulatory Point Of View
This past year was a busy one for regulators and regulated alike in the EU. We take a look at some of the key events from 2017.
You may also be interested in...
Big data may be prolonging development times for new pharmaceuticals, as companies struggle to cope with diverse digital applications and clinical trial protocol changes.
The European Medicines Agency rejected all seven eligibility requests for its priority medicines scheme that it reviewed in December.
After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.